LSO-092 Safety, efficacy and pharmacodynamics of cenerimod in patients with systemic lupus erythematosus: two randomised, double-blind phase 2 clinical trials

• Peter Cornelisse,
• Sandra V Navarra,
• Osamu Togo,
• Ouali Berkani,
• Clélia Cahuzac,
• Yoshinari Yokoyama

Affiliations

Peter Cornelisse

4Biometry, Idorsia Pharmaceuticals Ltd., Switzerland

Sandra V Navarra

1Rheumatology, University of Santo Tomas, Philippines

Osamu Togo

4Biometry, Idorsia Pharmaceuticals Japan Ltd, Japan

Ouali Berkani

3Clinical Science, Idorsia Pharmaceuticals Ltd., Switzerland

Clélia Cahuzac

4Biometry, Idorsia Pharmaceuticals Ltd., Switzerland

Yoshinari Yokoyama

3Clinical Development, Idorsia Pharmaceuticals Japan Ltd, Japan